Nurix Therapeutics CEO Arthur Sands' 2020 pay jumps 1,041% to $17M
Nurix Therapeutics reports 2020 executive compensation
By ExecPay News
Published: March 25, 2021
Nurix Therapeutics reported fiscal year 2020 executive compensation information on March 25, 2021.
In 2020, three executives at Nurix Therapeutics received on average a compensation package of $6.6M, a 505% increase compared to previous year.
Average pay of disclosed executives at Nurix Therapeutics
Arthur T. Sands, Chief Executive Officer, received $17M in total, which increased by 1,041% compared to 2019. 95% of Sands' compensation, or $16M, was in option awards. Sands also received $328K in non-equity incentive plan, $521K in salary, as well as $3.5K in other compensation.
Gwenn Hansen, Chief Scientific Officer, received a compensation package of $1.6M, which increased by 123% compared to previous year. 57% of the compensation package, or $879K, was in option awards.
Christine Ring, General Counsel, earned $1.3M in 2020.
Nurix Therapeutics' fiscal year ends on November 30.
Related executives
You may also like
Source: SEC filing on March 25, 2021.